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HPV vaccine: Why the rush?
To the Editor: It was disconcerting, not to say frightening, to see that 
at the time of writing, only weeks after the launch of the national 
campaign of human papillomavirus (HPV) vaccination of grade 4 
girls in South African (SA) public schools, a number of countries had 
put a moratorium on HPV vaccines. The Japanese government has 
done so more recently.[1] Austria has rejected the inclusion of HPV 
in its vaccination schedule. The Green Party MPs at the European 
Parliament are preparing to call for a moratorium in France.[1]
The reasons are many. Evidence of effectiveness has not yet been 
provided. Clinical trials were carried out without proof of safety, since 
there was no placebo arm. Adverse reactions as serious as permanent 
disability or even death (139 deaths so far)[2] are likely to result from 
the aluminium adjuvant that accumulates in the central nervous 
system.[3] The goal – the prevention of cervical cancer – remains to 
be proven. Finally, the two existing vaccines ‘protect’ only against two 
out of ten or more high-risk HPV types.[3-7]
Ever since gaining Food and Drug Administration approval in 
2006, Merck has been heavily criticised in the USA for their overly 
aggressive lobbying campaigns and marketing strategies.[4] Further, the 
vast majority of publications on the topic have been authored by Merck 
or GlaxoSmithKline (GSK) employees, or researchers employed by or 
funded by these companies.[8] To declare one’s conflict of interest in a 
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scientific paper does not per se make one unbiased.[8,9] Of note is the fact 
that even publications by independent researchers rely on data funded by 
the vaccine manufacturers, which makes their opinion questionable.[4] On 
the other hand, the reader may point out that the expressed caution-
ary views reflect only a limited number of independent authors. This 
may be attributable to powerful lobbying by the industry.[4]
SA media such as SAfm advertise the campaign and mention GSK’s 
sponsorship, an overt use by GSK of public media for personal gain. 
This use is of concern in view of the billions of US dollars GSK had 
to pay for bribery in the USA, and is currently under investigation 
in China, the UK and Poland for the same reason.[10] On air, the 
argument used to entice parents to have their daughters vaccinated is 
to prevent 3 000 women from dying of cervical cancer annually. This 
is misleading, since it will take at least another 20 years to find out 
if this will materialise.[9] Meanwhile, screening and follow-up remain 
necessary even for vaccinated women, who may well forget about 
them in view of the claimed benefits of vaccination.
These are the author’s views and not those of the National Health 
Laboratory Service or the University of Limpopo. The author declares no 
financial link or interest with GSK and Merck.
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